Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company’s intravenous Deciparticle™ formulation of everolimus. These findings will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9–12.

Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV) Deciparticle™ formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of oral everolimus (Afinitor®). The data indicate that Sapu003 may offer improved tolerability while preserving the drug’s intrinsic metabolic profile and enabling more consistent systemic exposure.

Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, ascomycin macrolactams, and polyketides—while maintaining a precise sub-20 nm nanoparticle profile suitable for intravenous (IV) delivery.

Oncotelic released a scientific survey paper detailing the Deciparticle™ nanomedicine platform and its potential applications in oncology. The publication summarizes design principles, tumor penetration characteristics, and the rationale supporting Sapu Nano’s Deciparticle-based programs. Inquiries routed through Oncotelic IR.

Focuses on Sapu-003 Deciparticle Everolimus data at SABCS in Texas. IR handled via Oncotelic.

Highlights Ingenue CRO coordination for the Australian symposium. Contact via Oncotelic IR.

References Australian HREC approval and Ingenue CRO as CTN-support partner. External inquiries routed through Oncotelic IR.